SDHB Large Deletions Are Associated with Absence of MIBG Uptake in Metastatic Lesions of Malignant Paragangliomas

Lenders J, Duh Q, Eisenhofer G, Gimenez-Roqueplo A, Grebe S, Murad M . Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(6):1915-42. DOI: 10.1210/jc.2014-1498. View

Dahia P, Clifton-Bligh R, Gimenez-Roqueplo A, Robledo M, Jimenez C . HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop. Endocr Relat Cancer. 2020; 27(8):T41-T52. PMC: 7334096. DOI: 10.1530/ERC-19-0435. View

Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L . Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019; 104(6):2367-2374. DOI: 10.1210/jc.2018-01968. View

Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J . Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007; 92(10):3822-8. DOI: 10.1210/jc.2007-0709. View

Ayala-Ramirez M, Feng L, Johnson M, Ejaz S, Habra M, Rich T . Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2010; 96(3):717-25. DOI: 10.1210/jc.2010-1946. View

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson A, Johnson A . Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell. 2017; 31(2):181-193. PMC: 5643159. DOI: 10.1016/j.ccell.2017.01.001. View

Ilias I, Chen C, Carrasquillo J, Whatley M, Ling A, Lazurova I . Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008; 49(10):1613-9. PMC: 2614907. DOI: 10.2967/jnumed.108.052373. View

Baudin E, Habra M, Deschamps F, Cote G, Dumont F, Cabanillas M . Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014; 171(3):R111-22. DOI: 10.1530/EJE-14-0113. View

Timmers H, Kozupa A, Chen C, Carrasquillo J, Ling A, Eisenhofer G . Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007; 25(16):2262-9. DOI: 10.1200/JCO.2006.09.6297. View

10.

De Luca A, Bottillo I, Dasdia M, Morella A, Lanari V, Bernardini L . Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet. 2007; 44(12):800-8. PMC: 2652822. DOI: 10.1136/jmg.2007.053785. View

11.

Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma D, Loaiza-Bonilla A . mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer. 2017; 24(8):L51-L55. DOI: 10.1530/ERC-17-0086. View

12.

Fonte J, Robles J, Chen C, Reynolds J, Whatley M, Ling A . False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2011; 19(1):83-93. PMC: 3420013. DOI: 10.1530/ERC-11-0243. View

13.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt T, Kreft A . 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine.... J Clin Endocrinol Metab. 2010; 95(6):2800-10. DOI: 10.1210/jc.2009-2352. View

14.

McWhinney S, Pilarski R, Forrester S, Schneider M, Sarquis M, Dias E . Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J Clin Endocrinol Metab. 2004; 89(11):5694-9. DOI: 10.1210/jc.2004-0769. View

15.

Cascon A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Leton R, Rodriguez-Antona C . Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot?. Genes Chromosomes Cancer. 2005; 45(3):213-9. DOI: 10.1002/gcc.20283. View

16.

Solis D, Burnichon N, Timmers H, Raygada M, Kozupa A, Merino M . Penetrance and clinical consequences of a gross SDHB deletion in a large family. Clin Genet. 2009; 75(4):354-63. PMC: 4718153. DOI: 10.1111/j.1399-0004.2009.01157.x. View

17.

Cascon A, Landa I, Lopez-Jimenez E, Diez-Hernandez A, Buchta M, Montero-Conde C . Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet. 2007; 45(4):233-8. DOI: 10.1136/jmg.2007.054965. View

18.

Martins R, Nunes J, Maximo V, Soares P, Peixoto J, Catarino T . A founder SDHB mutation in Portuguese paraganglioma patients. Endocr Relat Cancer. 2013; 20(6):L23-6. DOI: 10.1530/ERC-12-0399. View